Ozempic stays in your system for about 5 weeks after your last dose.
Semaglutide (the active ingredient in Ozempic) has an elimination half-life of approximately 1 week (~165 hours per the FDA label). It takes about 5 half-lives to fully clear a drug, which means Ozempic stays measurably in your system for around 5 weeks (35 days) after your final injection. Steady-state concentration is reached after 4-5 weekly doses when starting. Below is the complete clearance timeline by week, why this matters for surgery prep (ASA recommends holding Ozempic 1 week before procedures), pre-pregnancy washout (2 months minimum), switching to other GLP-1 drugs, and how long side effects last after stopping.
Quick Answer: How Long Does Ozempic Stay in Your System?
About 5 weeks after your last dose. Semaglutide's elimination half-life is approximately 1 week (165 hours), meaning the drug concentration halves every 7 days after stopping. Standard pharmacology principle: a drug is considered clinically cleared after 5 half-lives, when ~97% has been eliminated. For Ozempic, that's 35 days (5 weeks).
Practical implications by week after your last dose:
- Week 1: ~50% of the drug remaining
- Week 2: ~25% remaining
- Week 3: ~12.5% remaining
- Week 4: ~6% remaining
- Week 5: ~3% remaining (functionally cleared)
- Week 6+: Trace amounts only
🔑 Key Takeaways
- Half-life is about 1 week (165 hours). This is the FDA-labeled pharmacology value. Long half-life is why Ozempic is dosed weekly, not daily.
- Full clearance takes 5 weeks. 5 half-lives is the standard pharmacology rule for ~97% elimination. Plan all stopping-related decisions around this window.
- Pre-surgery: hold Ozempic 1 week. Per American Society of Anesthesiologists (ASA) 2023 consensus on GLP-1 drugs and preoperative care. Same applies before colonoscopy, endoscopy, and other procedures requiring an empty stomach.
- Pre-pregnancy: stop 2 months before conception. Standard washout per the FDA label and ACOG guidance. The drug clears in 5 weeks, but the 2-month buffer accounts for individual variation.
- Side effects fade in 2-6 weeks after stopping. Nausea resolves first; constipation persists longest; appetite and food noise return within 3-5 weeks.
Semaglutide Half-Life and Why It Matters
The half-life of a drug is the time it takes for its plasma concentration to drop by 50%. Semaglutide's half-life is unusually long for a peptide drug, approximately 165 hours (~1 week), thanks to its modified structure: a fatty acid side chain that binds to albumin in the blood and slows elimination dramatically.
Three reasons this long half-life matters in practical terms:
- Once-weekly dosing is possible. Most peptide drugs need daily injection. Semaglutide's albumin binding lets it remain active for a full week.
- Steady state takes 4-5 doses. When you start Ozempic, the drug accumulates with each weekly injection. Full steady-state concentration (the level your body holds between doses) is reached after about 4-5 weekly doses, which is why titration to maintenance dose follows a 4-week pattern.
- Stopping doesn't mean immediate cessation. Side effects, appetite suppression, and drug effects fade gradually over weeks, not days, because clearance is slow.
Clearance Timeline: Week-by-Week After Your Last Dose
| Time after last dose | % drug remaining | What's happening |
|---|---|---|
| Day 0 (injection day) | 100% | Peak concentration reached 1-3 days post-injection (Tmax) |
| Week 1 | ~50% | 1 half-life. Appetite suppression and side effects largely unchanged. |
| Week 2 | ~25% | Appetite begins returning. GI side effects (nausea, constipation) start fading. |
| Week 3 | ~12.5% | Food noise returns for most users. Significant appetite rebound. |
| Week 4 | ~6% | Drug is functionally low; most effects gone. Some users feel "back to baseline." |
| Week 5 | ~3% | Considered clinically cleared (5 half-lives = ~97% eliminated). |
| Week 6-8 | Trace amounts | No clinically detectable drug effect for most users. |
How Long to Reach Steady State on Ozempic
Steady state is the equilibrium where the amount of drug entering your body each week equals the amount eliminated. For Ozempic, steady state is reached after approximately 4-5 weekly doses at any given dose level.
Why this matters:
- Each dose increase resets the clock. Going from 0.25 mg to 0.5 mg means another 4-5 weeks to reach steady state at the new level. This is why the standard titration is 4-week dose escalations.
- Side effects peak as steady state builds. Weeks 1-2 of each new dose have the lowest tolerance because plasma levels are rising. Patience through this window is what gets most users to the maintenance dose.
- Effects keep improving for ~4-5 weeks at each new dose. Don't judge a dose level's effectiveness until you've held it for 4-5 weeks.
Pharmacology Data Table (FDA Ozempic Label)
| Parameter | Value | Notes |
|---|---|---|
| Elimination half-life (t1/2) | ~1 week (~165 hours / 7 days) | FDA label section 12.3 |
| Time to peak concentration (Tmax) | 1 to 3 days post-injection | FDA label section 12.3 |
| Absolute bioavailability (SC) | 89% | Subcutaneous injection |
| Time to steady state | 4 to 5 weekly doses | At any new dose level |
| Time to ~97% clearance after stopping | ~5 weeks (5 half-lives) | Standard pharmacology rule |
| Apparent clearance | 0.05 L/h | Slow due to albumin binding |
| Volume of distribution | ~12.5 L | Small Vd typical of peptide drugs |
| Plasma protein binding | >99% (to albumin) | The mechanism enabling weekly dosing |
| Steady-state mean concentration at 0.5 mg dose | ~65 ng/mL | FDA label section 12.3 |
| Steady-state mean concentration at 1.0 mg dose | ~123 ng/mL | FDA label section 12.3 |
| Metabolism | Proteolytic cleavage + beta-oxidation of fatty acid side chain | Not metabolized via CYP450 system; minimal drug-interaction risk |
| Excretion | Urine (~3%) and feces (~2% as intact drug); rest as metabolites | Most cleared as small peptide fragments |
How Long Ozempic Side Effects Last After Stopping
| Side effect | Time to resolution after last dose | What to expect |
|---|---|---|
| Nausea | 1-2 weeks | Resolves quickly as plasma levels drop |
| Vomiting | 1-2 weeks | Same as nausea |
| Diarrhea | 1-3 weeks | Resolves within first few weeks for most users |
| Constipation | 1-4 weeks | Persists longest of the GI side effects |
| Delayed gastric emptying / fullness | 2-6 weeks | Tracks with drug clearance |
| Appetite suppression | Returns at 3-5 weeks | Food noise comes back; gradual return to baseline appetite |
| Blood glucose effects (diabetics) | 4-8 weeks for fasting glucose; ~12 weeks for HbA1c rise | Diabetics need bridge therapy |
| Weight regain | 2-6 weeks for appetite-driven food intake return; weight regain over 6-12 months | About 2/3 of lost weight regained at 12 months per STEP 4 trial |
Pre-Surgery: When to Hold Ozempic (ASA 2023 Guidance)
The American Society of Anesthesiologists (ASA) issued consensus guidance in June 2023 specifically about GLP-1 receptor agonists like Ozempic before elective procedures. The concern: Ozempic delays gastric emptying, which means food and stomach contents may still be present when you go under anesthesia, even after standard 8-hour fasting. That creates aspiration risk during intubation.
The ASA recommendation:
- For weekly-dosed semaglutide (Ozempic, Wegovy): Hold the dose for at least 1 week before any elective procedure requiring anesthesia, sedation, or general anesthesia.
- For daily-dosed GLP-1s (Saxenda, Rybelsus): Hold on the day of the procedure.
- Day of procedure: Inform the anesthesia team you've been on a GLP-1 even if you held the dose; they may use ultrasound to assess gastric contents or treat you as a "full stomach" patient regardless.
Applies to:
- Elective surgery (orthopedic, cosmetic, abdominal, etc.)
- Colonoscopy and endoscopy
- Dental procedures requiring sedation
- Cardiac catheterization or other interventional procedures
- Childbirth (especially planned C-section)
For emergency surgery you cannot hold the dose; the anesthesia team manages aspiration risk with rapid-sequence intubation and other protocols.
Pre-Pregnancy: The 2-Month Washout Rule
Ozempic and Wegovy are both contraindicated in pregnancy. The FDA-approved labeling recommends discontinuing semaglutide at least 2 months before a planned pregnancy. The drug's ~1-week half-life means full clearance takes about 5 weeks, but the 2-month buffer accounts for individual variation in clearance and gives a safety margin before conception.
Practical pre-pregnancy protocol:
- Stop Ozempic 8 weeks (2 months) before you plan to start trying to conceive
- If unplanned pregnancy is detected while on Ozempic, stop immediately and contact your OB
- Continue contraception (preferably non-oral, since Ozempic affects oral medication absorption) for the full 2 months
- Tell your OB about your Ozempic use; ongoing prenatal monitoring may include glucose and growth scans
See our broader GLP-1 pregnancy, fertility, and thyroid safety guide for the full discussion.
Switching from Ozempic to Wegovy, Mounjaro, or Zepbound
Switching to another GLP-1 drug is a common scenario (cost, supply, indication, or effectiveness reasons). The general rule: wait 1 week from your last Ozempic dose, then start the new drug at its lowest titration dose.
| Switching to | Wait period | Starting dose | Notes |
|---|---|---|---|
| Wegovy (same molecule, higher dose) | 1 week from last Ozempic dose | Wegovy 0.25 mg or your last Ozempic dose level, depending on prescriber | Same molecule; many prescribers continue at equivalent dose without re-titration. See Wegovy vs Ozempic. |
| Mounjaro (tirzepatide, T2D) | 1 week from last Ozempic dose | Mounjaro 2.5 mg starter | Different molecule (dual GLP-1+GIP); start at lowest titration. See Mounjaro vs Ozempic. |
| Zepbound (tirzepatide, obesity) | 1 week from last Ozempic dose | Zepbound 2.5 mg starter | Same drug as Mounjaro at obesity-indication dosing. |
| Saxenda (liraglutide, daily) | 1 week from last Ozempic dose | Saxenda 0.6 mg daily starter | Different GLP-1 molecule, daily dosing. |
| Rybelsus (oral semaglutide) | 1 week from last Ozempic dose | Rybelsus 3 mg daily starter | Same molecule, oral form for T2D. |
Does Dose, Kidney, or Liver Function Change Clearance?
Largely no, with minor exceptions:
- Dose: Half-life remains constant (~1 week) across all dose levels. Higher doses just produce higher peak and steady-state concentrations, but the clearance kinetics don't change.
- Renal impairment: Mild-to-severe kidney impairment doesn't meaningfully change semaglutide clearance because the drug is primarily metabolized by proteolytic cleavage (not renal excretion). Per FDA label, no dose adjustment is required for kidney disease.
- Hepatic impairment: Mild-to-severe hepatic impairment also doesn't meaningfully alter clearance. No dose adjustment per FDA label.
- Body weight: Heavier patients have slightly faster apparent clearance per body weight; this is accounted for in the dosing recommendations.
- Age: No clinically meaningful difference in pharmacokinetics in adults across the 18-85 age range.
Will Ozempic Show Up on a Drug Test?
No. Standard drug screens (employment, sports, legal) test for amphetamines, opioids, cannabis, cocaine, PCP, alcohol, benzodiazepines, and similar controlled substances. Semaglutide is not part of any standard drug screen. There is no dedicated semaglutide test available outside of specialized research lab assays.
If a specific medical test requires measuring semaglutide (rare; only in clinical trials or unusual diagnostic situations), the test uses LC-MS/MS plasma assays not available in routine commercial labs.
Frequently Asked Questions
References and Authoritative Sources
- FDA-approved prescribing information for Ozempic (semaglutide). Available at accessdata.fda.gov.
- American Society of Anesthesiologists. ASA Consensus-Based Guidance on Preoperative Management of Patients on Glucagon-Like Peptide-1 Receptor Agonists, June 2023.
- StatPearls: Semaglutide (NCBI Bookshelf, NBK603723). ncbi.nlm.nih.gov/books/NBK603723
- DailyMed: Ozempic prescribing information.
- MedlinePlus: Semaglutide (NLM patient drug information).
- Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity (STEP 4). JAMA. 2021;325(14):1414-1425.
Medical disclaimer: This article is for educational and informational purposes only and is not medical advice. Pharmacological data is sourced from the FDA-approved Ozempic prescribing information. Individual clearance and side effect durations vary. Talk to your prescriber before stopping Ozempic, especially before surgery, pregnancy, or switching to another GLP-1 drug.